Holen Sie sich die Stockscreener-App
34.72
3.76%
-1.19
Artivion Inc Aktie (AORT) Neueste Nachrichten
Artivion Q1 2026 Earnings Preview — May 7, Street Expects $0.12 EPS - AlphaStreet
Earnings Preview: Artivion to Report Financial Results Post-market on May 07 - Moomoo
Freedom Capital Markets initiates Artivion stock with buy rating By Investing.com - Investing.com Australia
Freedom Capital Markets initiates Artivion stock with buy rating - Investing.com
Ladenburg Thalmann upgrades Artivion (AORT) - MSN
MSN Money - MSN
Artivion, Inc. (NYSE:AORT) Sees Large Growth in Short Interest - MarketBeat
Artivion (AORT) to Release Quarterly Earnings on Thursday - MarketBeat
Artivion (AORT) soars 5.3%: Is further upside left in the stock? - MSN
Conestoga Capital Adds Artivion to Portfolio Amid Market Volatility - HarianBasis.co
Strong Catalysts Drive Artivion (AORT) - Insider Monkey
What are the risks of Artivion (AORT) stock today | Artivion Logs 40% EPS Miss Below Analyst EstimatesMoat - Newser
Artivion (NYSE:AORT) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Artivion's next earnings update lands May 7, with a 4:30 p.m. ET webcast - Stock Titan
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results - marketscreener.com
AORT (Artivion Inc.) shares fall 1.26% after Q4 2025 EPS lands 40% below consensus analyst estimates.Social Investment Platform - Cổng thông tin điện tử tỉnh Lào Cai
AORT (Artivion) shares climb 2.86 percent on the day despite a 40 percent Q4 2025 EPS miss versus analyst estimates.Retail Trader Ideas - Xã Thanh Hà
Price Action Overview | Artivion posts 40% EPS miss below Street estimatesPerformance Review - UBND thành phố Hải Phòng
Artivion (AORT) Stock: Price Action Overview | Artivion posts 40% EPS miss below Street estimatesPerformance Review - Cổng thông tin điện tử tỉnh Lào Cai
Artivion, Inc. (NYSE:AORT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Will FDA Approval Of NEXUS And Endospan Option Reshape Artivion's (AORT) Minimally Invasive Aortic Strategy - simplywall.st
Artivion (AORT) Gains Conviction List Spot with Strong Buy Ratin - GuruFocus
Artivion, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
Artivion shows improved relative strength; still shy of benchmark - MSN
How The Investment Story Is Shifting For Artivion (AORT) After Recent Analyst And FDA Updates - Yahoo Finance
Artivion (AORT) Stock: Why It Matters This Year (-1.95%) 2026-04-16Crowd Risk Alerts - UBND thành phố Hải Phòng
Assessing Artivion (AORT) Valuation After FDA Approval Of NEXUS Aortic Arch System - simplywall.st
Tudor Investment Corp ET AL Sells 39,388 Shares of Artivion, Inc. $AORT - MarketBeat
Artivion (NYSE:AORT) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 85 Tel - GuruFocus
LADENBURG THALM/SH SH Upgrades Artivion (NYSE:AORT) to Buy - MarketBeat
Endospan’s FDA nod for Nexus brings acquisition by Artivion closer - BioWorld News
Growth Value: Is Artivion Inc a momentum stock2026 Growth vs Value & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Artivion secures FDA approval for NEXUS aortic arch system - MSN
Artivion Receives FDA Clearance for NEXUS Aortic Arch System - Bitget
Artivion Secures FDA Approval for NEXUS Aortic Arch System - Zacks Investment Research
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
UnitedHealth, Alignment Healthcare, Humana And Other Big Stocks Moving Higher On Tuesday - Sahm
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know - Yahoo Finance
Artivion, Inc. (AORT) Stock forecasts - Yahoo Finance UK
Artivion (AORT) Receives "Buy" Rating Reiteration from Needham | - GuruFocus
0.76%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):